Biotech Values

[DewDiligence]

If MRK intends to submit the Boceprevir NDA in 2010, as the company stated today, Boceprevir has pulled almost even with Telaprevir in the timing of a potential US launch. Before the MRK-SGP merger, SGP had told investors to expect a Boceprevir NDA in 2011 and FDA approval in 2012; clearly, something changed.